Kazazian Asset Management LLC raised its stake in Clovis Oncology (NASDAQ:CLVS) by 11.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,517 shares of the biopharmaceutical company’s stock after acquiring an additional 2,024 shares during the quarter. Clovis Oncology comprises 1.4% of Kazazian Asset Management LLC’s holdings, making the stock its 20th largest position. Kazazian Asset Management LLC’s holdings in Clovis Oncology were worth $1,327,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in CLVS. Cypress Capital Management LLC WY grew its position in shares of Clovis Oncology by 272.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares in the last quarter. Commonwealth Equity Services Inc acquired a new position in shares of Clovis Oncology during the 3rd quarter worth approximately $239,000. First Republic Investment Management Inc. acquired a new position in shares of Clovis Oncology during the 3rd quarter worth approximately $251,000. BB&T Securities LLC acquired a new position in shares of Clovis Oncology during the 3rd quarter worth approximately $288,000. Finally, Advisors Asset Management Inc. grew its position in shares of Clovis Oncology by 175.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 5,229 shares of the biopharmaceutical company’s stock worth $431,000 after purchasing an additional 3,334 shares in the last quarter.
A number of brokerages have issued reports on CLVS. Credit Suisse Group set a $86.00 target price on shares of Clovis Oncology and gave the stock a “buy” rating in a research report on Friday. Cann began coverage on shares of Clovis Oncology in a research report on Friday, March 23rd. They set a “hold” rating on the stock. BidaskClub upgraded shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday, March 29th. SunTrust Banks reduced their price target on shares of Clovis Oncology from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $88.57.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $54.09, for a total transaction of $162,270.00. Following the completion of the transaction, the insider now owns 180,571 shares of the company’s stock, valued at $9,767,085.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $64.97, for a total transaction of $292,365.00. Following the transaction, the director now directly owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. In the last three months, insiders sold 19,500 shares of company stock valued at $1,178,730. 12.50% of the stock is owned by insiders.
NASDAQ:CLVS traded up $3.07 on Friday, hitting $55.52. The company had a trading volume of 3,467,194 shares, compared to its average volume of 806,887. The company has a market cap of $2,652.56, a price-to-earnings ratio of -10.84 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. The business had revenue of $17.04 million during the quarter, compared to the consensus estimate of $19.42 million. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The firm’s revenue was up 21746.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.83) EPS. analysts expect that Clovis Oncology will post -4.85 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Kazazian Asset Management LLC Has $1.33 Million Position in Clovis Oncology (NASDAQ:CLVS)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/kazazian-asset-management-llc-has-1-33-million-stake-in-clovis-oncology-inc-clvs.html.
Clovis Oncology Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.